Prostate cancer drug developed in BC

Issue: BCMJ, vol. 52 , No. 7 , September 2010 , Pages 366 News

BC scientists have developed an ex­perimental drug shown to shrink pros­tate cancer tumors in a laboratory environment. The drug, EPI-001, targets a protein believed to be res­pon­sible for the fatal progression of advanced-stage prostate cancer. 

Re­search is being conducted by Dr Marianne Sadar, senior scientist at the BC Cancer Agency, and Dr Raymond Andersen, a professor at the University of British Columbia.

While previous prostate cancer drug research focused on one area of the androgen receptor protein, Dr Sadar discovered in 2007 that that an area at the opposite end of the protein structure, the N-terminal, was implicated in advanced prostate cancer.

Based on this discovery, Drs Sadar and Andersen collaborated to find a drug that would work on this target to delay or prevent the growth of prostate cancer. EPI-001 is the first drug candidate developed to target the N-terminal of the androgen receptor, inhibiting androgen receptor activities including recently discovered constitutively active truncated splice variants for which there were no inhibitors until EPI-001. 

The drug has proven to reduce, and potentially cure, CRPC in xenografts—with very limited toxicity and side effects. 

While the initial lab results are promising, human clinical trials need to be undertaken.

Research on EPI-001 was supported by peer-reviewed grant funds from the Canadian Institutes of Health Research, the National Cancer Institute of Canada, and the US Army Medical Research and Materiel Command Prostate Cancer Research Program. 

The research was published in Cancer Cell 17(6)525-526.

. Prostate cancer drug developed in BC. BCMJ, Vol. 52, No. 7, September, 2010, Page(s) 366 - News.



Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.


For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org

BCMJ Guidelines for Authors

Leave a Reply